# Improving HIV-1 Control in Africa with Long Acting Antiretrovirals

> **NCT05546242** · PHASE3 · ACTIVE_NOT_RECRUITING · sponsor: **MRC/UVRI and LSHTM Uganda Research Unit** · enrollment: 540 (actual)

## Conditions studied

- HIV-1-infection

## Interventions

- **DRUG:** Cabotegravir/Rilpivirine
- **DRUG:** Antiretroviral

## Key facts

- **NCT ID:** NCT05546242
- **Lead sponsor:** MRC/UVRI and LSHTM Uganda Research Unit
- **Sponsor class:** OTHER
- **Phase:** PHASE3
- **Study type:** INTERVENTIONAL
- **Status:** ACTIVE_NOT_RECRUITING
- **Start date:** 2022-12-08
- **Primary completion:** 2025-04
- **Final completion:** 2026-03
- **Target enrollment:** 540 (ACTUAL)
- **Last updated:** 2024-09-27

## Collaborators

- [object Object]

## Primary source

ClinicalTrials.gov registry: https://clinicaltrials.gov/study/NCT05546242

## Citation

> US National Library of Medicine, ClinicalTrials.gov registration NCT05546242, "Improving HIV-1 Control in Africa with Long Acting Antiretrovirals". Retrieved via AI Analytics 2026-07-11 from https://api.ai-analytics.org/clinical/NCT05546242. Licensed CC0.

---

*[Clinical trials dataset](/datasets/clinical-trials) · CC0 1.0*